PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia.
Acta Pharm Sin B
; 12(4): 1913-1927, 2022 Apr.
Article
in En
| MEDLINE
| ID: mdl-35847518
AML; AML, acute myeloid; BFLS, BorjesonForssmanLehmann syndrome; CML, chronic myeloid leukemia; CX5461; ChIP, chromatin immunoprecipitation; Co-IP, co-immunoprecipitation; DFC, dense fibrillar component; Epigenetic; FC, fibrillar centers; FUrd, 5-fluorouridine; H3K27me1, histone H3 (mono-methyl K27); H3K27me2, histone H3 (di-methyl K27); H3K27me3, histone H3 (tri-methyl K27); H3K9me1, histone H3 (mono-methyl K9); H3K9me2, histone H3 (di-methyl K9); H3K9me3, histone H3 (tri-methyl K9); Leukemia; MPAL, mixed-phenotype acute leukemia; Methyltransferase; NLS, nuclear localization sequences; NoRC, nucleolar chromatin remodeling complex; NuRD, nucleosome remodeling and deacetylase; PHF6; PHF6, plant homeodomain-like finger protein 6; RNA Pol I, RNA polymerase I; Re-ChIP, double chromatin immunoprecipitation; SUV39H1; SUV39H1, suppressor of variegation 3-9 homolog 1; T-ALL, T-cell acute lymphoblastic leukemia; UBF1, upstream binding factor 1; pre-rRNA, pre-ribosme RNA; rDNA transcription; rDNA, ribosomal DNA; rRNA, ribosome RNA
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Acta Pharm Sin B
Year:
2022
Document type:
Article
Affiliation country: